What is VIP?
VIP stands for vasoactive intestinal peptide, a naturally occurring 28-amino-acid neuropeptide found throughout the nervous system and numerous peripheral tissues. Despite its name, VIP is not limited to the intestine and participates in signalling involving the gastrointestinal, cardiovascular, respiratory, nervous and immune systems.
VIP is an established endogenous signalling molecule with well-characterised receptors and physiological functions. This should be distinguished from experimental research investigating whether externally administered VIP or compounds targeting its receptors could have clinical applications.
Vasoactive intestinal peptide
VIP was originally isolated from intestinal tissue and named for its ability to produce vasodilation alongside effects on gastrointestinal physiology.
Subsequent research demonstrated that VIP is widely distributed throughout the body. It functions both as a neuropeptide released from neurons and as a signalling molecule in peripheral tissues.
Its effects include regulation of smooth muscle, glandular secretion, vascular tone and communication between neural and immune systems. The exact response depends on the tissue, receptor subtype and surrounding physiological conditions.
Peptide structure
Human VIP consists of 28 amino-acid residues and belongs to the secretin/glucagon superfamily of peptide hormones.
Its amino-acid sequence is closely related to pituitary adenylate cyclase-activating polypeptide (PACAP), another neuropeptide with overlapping receptor activity.
Like many endogenous peptides, VIP can be rapidly broken down by enzymes. Its relatively short biological persistence has been an important consideration in pharmacological research involving VIP and synthetic analogues.
VPAC receptors
VIP produces many of its biological effects through two G-protein-coupled receptors known as VPAC1 and VPAC2.
Activation of these receptors commonly stimulates adenylate cyclase and increases intracellular cyclic AMP (cAMP), which can subsequently alter numerous cellular processes.
VPAC1 and VPAC2 are expressed in different patterns across the nervous system, gastrointestinal tract, lungs, blood vessels and immune cells. Their distribution helps explain why VIP can produce different physiological effects in different tissues.
VIP can also interact with the PAC1 receptor, although PACAP generally displays considerably greater selectivity for PAC1.
Nervous-system signalling
VIP is widely distributed in both the central and peripheral nervous systems. It functions as a neurotransmitter or neuromodulator within several neural pathways.
Research has established roles for VIP signalling in autonomic nervous-system activity and circadian biology. VIP-producing neurons within the suprachiasmatic nucleus, an important biological clock in the hypothalamus, participate in synchronising neuronal activity involved in daily physiological rhythms.
Experimental neuroscience has also investigated VIP in relation to neuronal communication, plasticity and interactions between neural and glial cells.
Gastrointestinal biology
The gastrointestinal tract was central to the original discovery of VIP and remains one of its best-characterised physiological environments.
VIP is released by enteric neurons and contributes to regulation of intestinal smooth muscle, gastrointestinal secretions and blood flow. It can promote relaxation of certain smooth-muscle tissues while influencing movement of water and electrolytes across intestinal surfaces.
The importance of normal VIP signalling is also illustrated by rare VIP-secreting neuroendocrine tumours, known as VIPomas, which can produce profound disturbances in intestinal secretion.
Vascular research
The term “vasoactive” reflects VIP's established ability to influence vascular smooth muscle. Activation of VIP receptors can promote vasodilation in several vascular beds and consequently alter local blood flow.
These effects involve intracellular signalling pathways including cAMP and interactions with mechanisms regulating vascular smooth-muscle tone.
However, the fact that endogenous VIP participates in vascular regulation does not establish externally supplied VIP as an appropriate treatment for cardiovascular conditions.
Immune signalling
VIP receptors are expressed on several types of immune cells, leading to substantial research into communication between VIP signalling and the immune system.
Experimental studies have investigated effects on cytokine production, lymphocyte activity, macrophages and other components of innate and adaptive immunity.
VIP is frequently described as immunomodulatory because its effects depend on the cell type and biological environment. Simplifying these interactions into a general claim that VIP “boosts” or “suppresses” immunity would not accurately represent the underlying biology.
Respiratory research
VIP is present within neural pathways associated with the respiratory system and has established effects on airway and vascular smooth muscle.
Its ability to influence bronchial smooth-muscle tone, pulmonary blood vessels and inflammatory signalling has led to experimental investigation in several respiratory contexts.
Clinical research involving VIP-related compounds has also occurred, but findings from particular formulations or disease populations cannot be generalised to all respiratory conditions or to independently produced VIP preparations.
Established physiological functions
Unlike many experimental peptides, VIP itself is a well-established endogenous human signalling molecule.
Its recognised physiology includes roles in smooth-muscle regulation, gastrointestinal secretion, vasodilation, autonomic signalling and communication within the nervous and immune systems. VIP signalling also contributes to circadian organisation through specialised neurons within the hypothalamus.
These established physiological roles describe what naturally occurring VIP does within regulated biological systems. They do not demonstrate that increasing VIP exposure produces beneficial clinical effects.
Experimental applications
Because VIP participates in several important signalling systems, researchers have investigated VIP and compounds targeting VPAC receptors across numerous experimental areas.
These include respiratory disease, inflammatory signalling, neurological biology and cardiovascular physiology. Researchers have also explored modified VIP analogues and alternative delivery systems because naturally occurring VIP is rapidly degraded.
Evidence varies substantially between applications. Mechanistic plausibility or positive results in animal models should not be treated as evidence of an established human therapy.
PACAP vs VIP
VIP and PACAP are closely related neuropeptides belonging to the same broader peptide family, but they are distinct molecules.
VIP contains 28 amino acids. PACAP occurs primarily as PACAP-38 and, to a lesser extent, the shorter PACAP-27 form.
Both VIP and PACAP activate VPAC1 and VPAC2 receptors. A major pharmacological distinction is that PACAP also has high affinity for the PAC1 receptor, whereas VIP has substantially lower activity at this receptor.
Their overlapping receptor biology means some physiological effects can appear similar, but evidence concerning PACAP should not automatically be attributed to VIP.
Frequently asked questions
What does VIP stand for?
VIP stands for vasoactive intestinal peptide.
How many amino acids does VIP contain?
Human VIP is a peptide containing 28 amino-acid residues.
Is VIP naturally produced by humans?
Yes. VIP is an endogenous neuropeptide produced in the nervous system and several peripheral tissues.
Does VIP only function in the intestine?
No. Despite its name, VIP has important signalling functions in the nervous, gastrointestinal, cardiovascular, respiratory and immune systems.
What are VPAC1 and VPAC2?
VPAC1 and VPAC2 are G-protein-coupled receptors through which VIP produces many of its physiological effects.
Is VIP the same as PACAP?
No. They are closely related peptides with overlapping activity at VPAC receptors, but PACAP additionally displays strong activity at the PAC1 receptor.
Does VIP's natural role prove therapeutic benefits from externally supplied VIP?
No. Establishing the physiological function of an endogenous peptide is different from demonstrating the safety and effectiveness of administering that peptide as an intervention.
Scientific references
Scientific literature on VIP includes extensive research into its discovery, 28-amino-acid structure, VPAC1 and VPAC2 receptor pharmacology, gastrointestinal physiology, vascular signalling, circadian biology, respiratory function and neuroimmune interactions. Experimental applications should be evaluated separately from established endogenous physiology, with human clinical claims tied to the exact formulation, population and endpoint investigated.